First patient treated with A3-Shield system in PRINCIPIIS FIH trial

PRINCIPIIS FIH Study Begins for Angiolutions A3 Shield System in Early Stage AAA

December 3, 2025—Angiolutions announced that the first patient has been treated in a first-in-human (FIH) study evaluating the safety and effectiveness of the company’s investigational A3 Shield system. According to the company, the PRINCIPIIS FIH trial is designed to evaluate the A3 Shield as an early interventional option for patients with small abdominal aortic aneurysms (AAAs). The trial is being conducted at several centers in Tashkent, Uzb…

First patient treated with A3-Shield system in PRINCIPIIS FIH trial

The PRINCIPIIS-FIH trial team after the successful implantation (l–r): Mansur Duran, Marcus Wenzel, Isabel N Schellinger, Marius Rummel, Sandra Düsing, Hubert Schelzig, Markus Wagenhäuser, and Uwe Raaz Angiolutions has announced that the first patient has been successfully treated with its investigational A3-Shield system in the PRINCIPIIS FIH trial, a first-in-human (FIH) study evaluating the device’s safety and effectiveness. The trial is bein…